Mannitol as an Excipient for Lyophilized Injectable Formulations.
Bulking agent
Differential scanning calorimetry (DSC)
Excipients
Hydrate(s)
Injectables
Lyophilization
Mannitol
Polymorphs
Sucrose
Trehalose
X-ray Powder diffraction (XRD)
Journal
Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
11
06
2022
revised:
19
08
2022
accepted:
20
08
2022
pubmed:
29
8
2022
medline:
21
12
2022
entrez:
28
8
2022
Statut:
ppublish
Résumé
The review summarizes the current state of knowledge of mannitol as an excipient in lyophilized injectable small and large molecule formulations. When compared with glycine, the physicochemical properties of mannitol make it a desirable and preferred bulking agent. Though mannitol is a popular bulking agent in freeze-dried formulations, its use may pose certain challenges such as vial breakage or its existence as a metastable crystalline hemihydrate in the final cake, necessitating appropriate mitigation strategies. The understanding of the phase behavior of mannitol in aqueous systems, during the various stages of freeze-drying, can be critical for the optimization of freeze-drying cycle parameters in multi-component formulations. Finally, using a decision tree as a guiding tool, we demonstrate the use of orthogonal techniques for attaining a stable and cost-effective lyophilized drug product containing mannitol.
Identifiants
pubmed: 36030846
pii: S0022-3549(22)00366-5
doi: 10.1016/j.xphs.2022.08.029
pii:
doi:
Substances chimiques
Excipients
0
Mannitol
3OWL53L36A
Sucrose
57-50-1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-35Informations de copyright
Copyright © 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interests The authors declare no competing financial interest.